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OBJECTIVE: The aim of this study was to analyze the out-
hospital cardiovascular drug utilization in the city of Nis. The
prevalence of cardiovascular disease is high in Serbia. Analysis
of cardiovascular drugs utilization in a population is the basis
for the assessment of cardiovascular pharmacotherapy.
METHODS: Using the ATC/DDD methodology, we analyzed the
utilization of cardiovascular drugs dispensed on prescription in
Nis region in 2003–2004. A retrospective study on cardiovascu-
lar drugs utilization according to ATC classiﬁcation, was con-
ducted on the basis of data received from Central City Pharmacy
Nis. RESULTS: Results were presented in DDD/1000 inhabi-
tants/day. The most frequently prescribed drug in 2003–2004
was Enalapril (32.16: 41.71 DDD/1000 inhabitants/day. Besides,
consumption of other ACE inhibitors was small (2.94 :6.48
DDD/1000 inhabitants/day). The next most commonly used
drugs were selective beta blockers (atenolol-8.48DDD/1000
inhabitants/day; metoprolol 5.85 DDD/1000 inhabitants/day) in
2003. The use of amlodipin had a signiﬁcant increase in 2004
(10.21 DDD/1000 inhabitants/day: 6.41 DDD/1000 inhabi-
tants/day). Marginal use of diuretics was detected (4.48
DDD/1000 inhabitants/day: 5.19 DDD/1000 inhabitants/day).
CONCLUSION: The present analysis for 2003–2004 pointed to
therapeutic irrationalities which could be overcome with educa-
tion concerning cardiovascular drugs consumption in Nis region
(south-east Serbia).
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OBJECTIVES: To analyse the utilisation of antihypertensive
drugs within Slovakia between 2000 and 2004 and to asses 
the economic consequences of antihypertensive medications.
METHODS: For 2000–2004, the data about consumption of
drugs for cardiovascular disease were collected, in accordance
with the Anatomic Therapeutic Chemical classiﬁcation (ATC:
C01- C10) and Deﬁned Daily Dose (DDD) measurement unit.
This analysis focused on the situation in antihypertensive med-
ication in more detail. Data of wholesalers, who are legally
obliged provide this information to the SUKL, was used for the
analysis. RESULTS: A signiﬁcant increase in the medication of
cardiovascular disease (in 2000 (290.27), in 2002 (376.30) and
in 2004 (388.06) in term of DDD/1000/day can be seen from
this analysis. The results show that the consumption (in term of
DDD/1000/day) of ß-blockers was (in 2000 (32.04), in 2002
(41.91) and in 2004 (42.78)), ACE inhibitors (in 2000 (57.01),
in 2002 (81.86) and in 2004 (88.79)), Ca-blockers (in 2000
(39.72), in 2002 (55.42) and in 2004 (63.25)), diuretics (in 2000
(28.20), in 2002 (32.82) and in 2004 (31.67)), peripheral
vasodilators (in 2000 (20.89), in 2002 (22.12) and in 2004
(19.63)), vasoprotectives (in 2000 (33.89), in 2002 (41.67) and
in 2004 (34.23)), serum lipid reducing agents (in 2000 (12.79),
in 2002 (22.18) and in 2004 (31.50)). In ﬁnancial terms, the 
consumption of ß-blockers in 2000 (€7,024,000) and 2004
(€10,515,000), ACE inhibitors in 2000 (€18,714,000) and 
2004 (€32,290,000), Ca-blockers in 2000 (€16,971,000) and
2004 (€19,454,000), diuretics in 2000 (€1,609,000) and 2004
(€2,478,000) can be seen from this study. CONCLUSIONS:
Inseparable components of the Slovak drug policy must be
viewed realistically with regard to the antihypertensive drugs’
consumption. Adherence to principles of antihypertensive treat-
ment’s guidelines lead to fundamental short and long term ﬁnan-
cial savings within health care systems.
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OBJETIVE: To estimate the cost-effectiveness of 160mg valsar-
tan as an alternative treatment for systemic arterial hypertension
as compared with daily doses of 100mg losartan and 80mg
telmisartan using a pharmaco-economic analysis. METHOD-
OLOGY: The study was based on a literature review and expert
opinion in two phases: the ﬁrst was a literature search to deter-
mine effectiveness expressed as a reduction of mm Hg; the
second consisted of a cost-effectiveness analysis. The model used
the Mexican Health System perspective. Only direct medical
costs were included. Data costs were obtained from published
lists of unitary costs for the Health Sector. RESULTS: Following
treatment with 160mg valsartan and 100mg losartan for 4
weeks, the mean sitting diastolic blood pressure (MSDBP) was 
-10.5mmHg and -9.7mmHg respectively. The difference was
not signiﬁcantly signiﬁcant. In the case of valsartan versus 80mg
telmisartan, valsartan proved more effectiveness, showing a
reduction in systolic and diastolic pressure of -18.6 and 
-12.1mmHg respectively as compared with reductions of -10.8
and -8.4mmHg for telmisartan. The cost analysis did not show
any differences in terms of other medical interventions but there
was a difference in the cost of the drugs. The monthly cost per
patient treated was the lowest with 160mg valsartan at $246.67
Mexican pesos (US$22.42), as compared with $695.60 Mexican
pesos (US$63.23) for 100mg losartan and $469.29 ($42.66) for
80mg telmisartan. CONCLUSIONS: Treatment with 160mg
valsartan is the least costly with at least the same efﬁcacy in
reducing arterial pressure as 100mg daily dose of losartan. In
the case of 80mg telmisartan, 160mg valsartan was more effec-
tive with a lower cost. It has been shown that 160mg valsartan
is the preferred treatment in terms of pharmaco-economic para-
meters compared with the other options studied. Sensitivity
analysis conﬁrmed the results obtained in the base case.
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OBJECTIVES: To investigate if there are differences in the per-
sistence and compliance to therapy depending on the antihyper-
tensive drug class prescribed ﬁrst (index drug). METHODS:
Prescription claims data were analysed for the 2000 to 2003 time
period. Index prescriptions were determined for: ACE-inhibitors
(ACEi), angiotensin receptor blockers (ARB), beta blockers
(BETA), calcium channel blockers (CCB), and diuretics (DIU).
Patients regarded as newly diagnosed (i.e., without any antihy-
pertensive medication 180 days before the index time point) with
a follow-up of at least 360 days were included in the study. Per-
sistence rates (percentage of beneﬁciaries on continuous therapy
with the index drug at 180 and 360 days) were calculated for
each drug class. Compliance was determined in terms of the med-
ication possession ratio (MPR) for 180 and 360 days (dispensed
supply in deﬁned daily dose (DDD) within 180 and 360 days
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divided by the total number of days). RESULTS: Most of the
62,754 beneﬁciaries had an index prescription of BETA, fol-
lowed by ACEi, DIU, CCB, and ARB. Persistence rates at 180
and 360 days were highest for ARB (71.0 and 52.7%, valsartan
77.1 and 59.3%), followed by CCB (51.5 and 34.4%), ACEi
(50.2 and 34.5%), DIU (41.3 and 26.0%), and BETA (25.1 and
13.6%). After adjusting for age, sex, and diabetic comorbidity,
the persistence remained signiﬁcantly higher for ARB compared
to all other drug classes. The MPR for 180 and 360 days showed
a similar pattern with the highest ratio for ARB (0.88 and 0.84;
valsartan 0.92 and 0.87), followed by CCB (0.73 and 0.66),
ACEi (0.72 and 0.67), DIU (0.70 and 0.63), and BETA (0.51 and
0.45). CONCLUSION: ARBs, and valsartan as a representative
of the class, showed the highest persistence and compliance sug-
gesting that a more sustained blood pressure control could be
expected from utilization of ARBs and Valsartan.
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Lack of compliance is a major factor responsible for the differ-
ences between clinical trial results and real effectiveness in daily
medical practice, contributing to an insufﬁcient control of the
cardiovascular risk factors (CVRF). Knowledge of the factors
contributing to lack of compliance is limited, and in Spain data
are scarce. OBJECTIVES: 1) To indirectly determine the level of
compliance among patients with hypertension and/or dyslipi-
demia; 2) To determine factors associated with compliance.
Patients and METHODS: A total of 9001 hypertensive and/or
dyslipidemic patients from four primary care centres in Catalo-
nia were enrolled in Disease Management programmes during
the previous four years. Compliance was estimated by the rela-
tionship between the amount of dispensed and prescribed pills.
1) The levels of compliance of dyslipidemic patients without
hypertension (DL-non HT), hypertensive patients with dyslipi-
demia (HT + DL) and hypertensives without dyslipidemia 
(HT-non DL) were compared. 2) An stepwise, multivariate,
descriptive; multiple regression model was designed in order to
explain compliance. RESULTS: 1) Compliance was 79% in DL-
non HT, signiﬁcantly lower than in HT + DL (81.2%, p <
0.0001) and in HT-non DL (82.4%, p < 0.0001). There were
also statistically signiﬁcant differences between these last two
groups (p = 0.0014). 2) Explanatory variables of a better com-
pliance in the multivariate analysis were a) patient related
factors: labour inactivity (p < 0.0001); b) management related
factors: speciﬁc doctor (p < 0.0001) and intensity of follow-up
(p = 0.04) and c) drug related factors: the drug group (p <
0.0001); the drug price (the more price the more compliance (p
= 0.0062) and the number of active principles used (the more
number the more compliance, p = 0.019). CONCLUSIONS: 1)
Dyslipidemic patients show a worse compliance than hyperten-
sive patients, and dyslipidemia worsened global compliance in
hypertensive patients. 2) Patient characteristics, doctor attitude,
follow-up intensity, drug group and simplicity of treatment are
related to compliance in daily medical practice.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes of adding Niaspan® to statin treatment in patients with
persistently low HDL-c on statin monotherapy. METHODS:
Two models were developed to project long-term clinical and
economic outcomes. The ﬁrst model (second order Monte Carlo
simulation) simulated the evolution of lipid levels with treatment
and the second (Markov model) was designed to calculate the
risk of coronary heart disease (CHD) events each subsequent
year. Transition probabilities for CHD events were derived from
the Framingham risk formulae. Baseline cohort characteristics
and simvastatin treatment effects were taken from the 4S lipid
triad sub-group. Patients with persistently low HDL-c 
(<1.03mmol/L) on statin treatment received either add-on
Niaspan® 1g to 2g daily or continued statin monotherapy.
Niaspan® dosing followed maintenance dose recommendations
and treatment effects were taken from several clinical trials
(European SPC). Direct medical costs were accounted (cardio-
vascular complications and drug costs). Annual discount rates of
0% and 3.5% (Austria), 3% (Sweden and Norway) were applied
to clinical outcomes and costs. RESULTS: 68.9% of patients
were projected to have persistently low HDL-c levels after statin
treatment. In these patients mean undiscounted life expectancies
(LE) of 20.96 years and 20.46 years were projected for the
Niaspan® and statin monotherapy arms respectively. Lifetime
direct medical costs were higher by €8079 in Austria, €4723 in
Sweden and €5638 in Norway with addition of Niaspan®. Incre-
mental cost-effectiveness ratios based on discounted LE were
€16,306 (€17,635) per life year gained in Austria, €16,543
(€16,652) in Sweden and €19,748 (€21,194) in Norway for
statin plus Niaspan® 1g (and 2g) versus statin monotherapy.
CONCLUSIONS: In Austria, Sweden and Norway, raising HDL-
c with the addition of Niaspan® to statin therapy was projected
to be cost-effective compared to statin monotherapy in patients
with dyslipidemia and persistently low HDL-c.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes of adding Niaspan® to statin treatment in patients with
persistently low HDL-c on statin monotherapy. METHODS:
Two models were developed to project long-term clinical and
economic beneﬁts of treatment. The ﬁrst simulated the evolution
of lipid levels with treatment utilising second order Monte Carlo
methodology, and the second was designed to calculate the risk
of coronary heart disease (CHD) events each subsequent year
using standard Markov modeling techniques. Transition proba-
